Midazolam: Pharmacology and Clinical Use

Quick Answer

Midazolam is a short-acting benzodiazepine with anxiolytic, amnestic, sedative-hypnotic, and muscle relaxant properties. Mechanism: Positive allosteric modulation of GABA-A receptors (increases chloride conductance, hyperpolarizes neuron). Pharmacokinetics: Rapid onset (1-2 minutes IV), short duration (2-6 hours), high lipophilicity crosses BBB rapidly, metabolized by hepatic CYP3A4 to active metabolite α-hydroxymidazolam (50% potency of parent), excreted renally. Water-soluble at pH <4 (commercial preparation), lipid-soluble at physiological pH (crosses BBB). Clinical uses: Anxiolysis (0.02-0.04 mg/kg), conscious sedation (0.05-0.1 mg/kg), induction adjunct (0.1-0.3 mg/kg), premedication (0.05 mg/kg IV or 0.5 mg/kg PO in children), ICU sedation (infusion 0.03-0.2 mg/kg/hour). Reversal: Flumazenil 0.2-1 mg IV (competitive antagonist at GABA-A receptor, duration 30-60 minutes, shorter than midazolam - resedation possible). Caution: Elderly (prolonged effect), hepatic impairment, drug interactions (CYP3A4 inhibitors). [1-10]

Pharmacology

Chemical Structure and Properties

Structure:

• Class: Imidazobenzodiazepine (fused imidazole ring distinguishes from other benzodiazepines)
• Molecular weight: 325.8 Da
• pKa: 6.2
• Unique property: Water-soluble at acidic pH (<4), lipid-soluble at physiological pH
  • Commercial preparation pH 3-3.5 (clear solution, water-soluble)
  • After injection, pH 7.4 → ring opens → lipid-soluble (crosses BBB rapidly)

Advantages of Water Solubility:

• No pain on injection (cf. diazepam which requires propylene glycol solvent)
• No thrombophlebitis
• Can mix with other IV solutions
• No local irritation

Lipid Solubility at Physiological pH:

• High lipophilicity (log P 3.2)
• Rapid crossing of blood-brain barrier
• High brain uptake (onset 30-60 seconds IV)
• Rapid redistribution (short duration of action)

Mechanism of Action

GABA-A Receptor:

• Structure: Pentameric ligand-gated chloride channel
• Subunits: 2α, 2β, 1γ (most common α1β2γ2)
• Binding site: Benzodiazepine binding site (between α and γ subunits)
• Endogenous ligand: None (benzodiazepine binding site is distinct from GABA binding site)

Action of Midazolam:

• Allosteric modulator: Does not directly activate channel
• Enhances GABA binding: Increases affinity of GABA for its receptor
• Increases chloride conductance: Channel opens more frequently (not longer duration)
• Hyperpolarization: Neuron more negative inside → less excitable
• Result: Anxiolysis, sedation, amnesia, anticonvulsant, muscle relaxation

Clinical Effects from Receptor Subtypes:

• α1 subunit: Sedation, amnesia, anticonvulsant
• α2 subunit: Anxiolysis, muscle relaxation
• α3, α5: Less specific effects

No Effect on:

• Glutamate receptors (NMDA)
• Dopamine receptors
• Opioid receptors
• Glycine receptors

Pharmacokinetics

Absorption:

• IV: 100% bioavailability, onset 30-60 seconds
• IM: Rapid absorption, 90% bioavailability, onset 5-15 minutes
• Oral: 40-50% bioavailability (first-pass metabolism), onset 15-30 minutes
• Intranasal: 50-60% bioavailability, rapid onset (avoid - irritating)
• Rectal: Variable absorption, 40-50% bioavailability
• Buccal: Rapid, used in children for sedation

Distribution:

• Volume of distribution (Vd): 1.1-1.5 L/kg
• Protein binding: 97% (albumin)
• Distribution half-life: 7-15 minutes (rapid redistribution)
• Blood-brain barrier: Rapid crossing due to high lipophilicity
• Redistribution: From brain to muscle and fat (terminates effect)

Metabolism:

• Primary pathway: Hepatic oxidation via CYP3A4 (90%)
• Active metabolites:
  • α-hydroxymidazolam: 50% potency of parent drug, contributes to effect
    • Half-life: 0.5-1 hour (shorter than midazolam in healthy patients)
    • Can accumulate in renal failure (prolonged sedation)
  • 4-hydroxymidazolam: Less active
• Genetic variation: CYP3A4 polymorphisms affect metabolism rate

Excretion:

• Route: Renal (glucuronide conjugates)
• Elimination half-life: 1.5-3 hours (healthy adults)
• Clearance: 6-11 mL/kg/min
• Context-sensitive half-time: Increases with duration of infusion (accumulation)

Factors Affecting Pharmacokinetics:

Age:

• Neonates: Reduced clearance, prolonged half-life (6-12 hours)
• Elderly:
  • Reduced clearance (↓hepatic blood flow, ↓CYP activity)
  • Increased Vd (↓muscle mass, ↑fat)
  • Increased sensitivity (↓receptor density)
  • Half-life 3-6 hours (double young adults)
  • Dose reduction: 50% or more

Organ Dysfunction:

• Hepatic impairment: Reduced metabolism, prolonged effect
  • Avoid or reduce dose significantly (25-50%)
• Renal failure:
  • Accumulation of active metabolite (α-hydroxymidazolam)
  • Prolonged sedation
  • Dose reduction needed
• Obesity: Increased Vd, may need dosing by lean body weight

Drug Interactions:

• CYP3A4 inhibitors (increase midazolam levels):
  • Erythromycin, clarithromycin (macrolides)
  • Protease inhibitors (ritonavir)
  • Azole antifungals (ketoconazole, fluconazole)
  • Calcium channel blockers (diltiazem, verapamil)
  • Grapefruit juice
  • Can increase midazolam concentration 2-10×
• CYP3A4 inducers (decrease midazolam levels):
  • Rifampicin
  • Carbamazepine
  • Phenytoin
  • St. John's wort
• Additive CNS depression:
  • Opioids (synergistic respiratory depression)
  • Alcohol
  • Other sedatives
  • Antihistamines

Pharmacodynamics

Central Nervous System:

Anxiolysis:

• Dose: 0.02-0.04 mg/kg IV
• Mechanism: Enhanced GABAergic inhibition in limbic system (amygdala)
• Effect: Calm, cooperative, reduced anxiety
• No euphoria (unlike opioids)

Sedation/Hypnosis:

• Dose: 0.05-0.1 mg/kg IV
• Stages:
  • Anxiolysis (low dose)
  • Sedation (moderate dose)
  • Hypnosis/sleep (higher dose)
  • General anaesthesia (very high dose - rarely used)
• EEG: Beta activity (activation) at low doses, then slowing

Amnesia:

• Anterograde amnesia: Cannot form new memories (most prominent effect)
• Duration: 20-40 minutes after single dose
• Mechanism: Impaired hippocampal function (GABA-mediated)
• Advantage: Patient does not remember unpleasant procedures
• Disadvantage: Can be distressing if patient realizes they cannot remember

Anticonvulsant:

• Mechanism: Enhanced GABA inhibition
• Efficacy: Less effective than other anticonvulsants
• Use: Acute seizures, alcohol withdrawal (benzodiazepines first-line), local anaesthetic toxicity

Muscle Relaxation:

• Mechanism: Supraspinal (CNS) effect, not neuromuscular junction
• Effect: Reduced muscle tone (not paralysis)
• Useful for: Endoscopy, minor procedures, tetanus

Respiratory System:

• Respiratory depression: Dose-dependent
  • Reduced tidal volume primarily
  • Reduced response to CO₂ (shift curve right)
  • Apnoea with high doses or with opioids
• Airway: Loss of tone, obstruction risk (especially in snorers, obese)
• Protective reflexes: Depressed (aspiration risk)
• Synergistic with opioids: Marked respiratory depression

Cardiovascular System:

• Heart rate: Minimal change or slight increase
• Blood pressure: Mild decrease (SVR reduction, vasodilation)
  • More pronounced in hypovolemic patients
  • Less than propofol
• Cardiac output: Minimal change
• Arrhythmias: Rare, antiarrhythmic (suppresses PVCs)
• Coronary blood flow: Preserved

Other Systems:

• Gastrointestinal: Reduced motility (constipation with chronic use)
• Genitourinary: Relaxation (useful for endoscopy)
• Thermoregulation: Impaired (chronic use)

Paradoxical Reactions (5-10% of patients):

• Agitation: Instead of sedation
• Disinhibition: Hyperactive, uncooperative
• Confusion: Especially elderly
• Delirium: Excitement, violence (rare)
• Mechanism: Paradoxical GABA-mediated excitation (downregulation of inhibition)
• Treatment: Flumazenil (reversal), switch to different agent (propofol, dexmedetomidine), physical restraints if necessary
• Risk factors: Elderly, children, high dose, rapid injection, pre-existing anxiety

Clinical Use

Premedication

Indications:

• Anxiolysis (most common use)
• Amnesia for preoperative events
• Anticipatory antiemetic (reduces PONV)
• Anticonvulsant (alcohol withdrawal, seizure prophylaxis)

Dosing:

• Adults: 0.05 mg/kg IV (2-4 mg typical) 5-10 minutes pre-induction
  • Reduce dose 50% in elderly
  • Reduce dose in hepatic/renal impairment
• Children: 0.5 mg/kg PO (max 20 mg) 30-45 minutes pre-procedure
  • Bitter taste - mix with juice/syrup
  • Can use 0.1 mg/kg intranasal (avoid - burns)
  • Buccal 0.2-0.3 mg/kg (rapid, effective)
• IM: 0.07-0.1 mg/kg (rarely used - painful)

Benefits:

• Smooth induction (reduces anxiety-related hypertension, tachycardia)
• Amnesia for preoperative period
• Reduced PONV
• Reduced propofol/induction agent requirements

Risks:

• Respiratory depression (especially with opioids)
• Paradoxical excitement (children, elderly)
• Prolonged recovery

Induction of Anaesthesia

Use:

• Adjunct to induction: Not sole agent (too slow, cardiovascular depression)
• Dose: 0.1-0.3 mg/kg IV (5-10 mg typical)
• Benefits:
  • Amnesia (if light anaesthesia)
  • Anxiolysis
  • Reduced induction agent requirements
• Drawbacks:
  • Prolonged emergence if used as part of TIVA
  • Active metabolites

Sedation for Procedures

Indications:

• Endoscopy (gastroscopy, colonoscopy, bronchoscopy)
• Dental procedures
• Minor surgery (cataract, dermatology)
• Cardioversion
• Imaging (MRI, CT in children or claustrophobic adults)
• ICU procedures (line insertion, bronchoscopy)

Technique:

• Incremental dosing: 1-2 mg IV q2-3 minutes titrated to effect
• Total dose: 0.05-0.1 mg/kg typical
• Monitoring: SpO₂, BP, ECG (capnography if deep sedation)
• Supplemental O₂: High flow (prevents desaturation)
• Airway: Maintain patency (jaw thrust if needed)
• Reversal: Flumazenil available

Combination with Opioids:

• Synergistic: Lower doses of both drugs needed
• Risk: Profound respiratory depression, airway obstruction
• Example: Midazolam 2 mg + fentanyl 50-100 μg for colonoscopy
• Monitoring: Essential (capnography recommended)

ICU Sedation

Use:

• Short-term sedation (<48-72 hours preferred)
• Mechanical ventilation
• Weaning (reduces anxiety, prevents self-extubation)

Technique:

• Bolus: 0.03-0.1 mg/kg then
• Infusion: 0.03-0.2 mg/kg/hour (1-5 mg/hour typical adult)
• Titration: To Ramsay score or RASS
• Daily interruption: Recommended (reduces duration, delirium)
• Switch to: Lorazepam if prolonged sedation needed (cheaper, no active metabolites)

Advantages:

• Rapid titration
• Anterograde amnesia
• Hemodynamic stability
• Reversible (flumazenil)

Disadvantages:

• Active metabolite accumulation (especially renal failure)
• Context-sensitive half-time (accumulates)
• Delirium (increases risk, especially elderly)
• Tolerance (requires dose escalation)
• Dependence (withdrawal if abrupt cessation after prolonged use)

Better Alternatives for ICU:

• Propofol: Rapid awakening, no accumulation (but lipid load, PRIS risk)
• Dexmedetomidine: No respiratory depression, anxiolysis, analgesia (bradycardia risk)
• Lorazepam: Cheaper, longer duration, no active metabolites (propylene glycol load)

Other Uses

Status Epilepticus:

• First-line (along with lorazepam)
• Dose: 0.1-0.2 mg/kg IV (repeat if needed)
• Follow with long-term anticonvulsant loading

Local Anaesthetic Toxicity:

• Part of treatment (along with lipid emulsion)
• Reduces seizure activity
• Dose: 0.05-0.1 mg/kg

Alcohol Withdrawal:

• First-line (along with diazepam)
• Symptom-triggered dosing (CIWA-Ar protocol)
• Prevents seizures, delirium tremens

Tetanus:

• Muscle relaxation (supraspinal)
• Sedation
• Often combined with neuromuscular blockade

Night Terror/Sleepwalking (Children):

• Low dose at bedtime
• Interrupts arousal cycle

Reversal with Flumazenil

Mechanism:

• Competitive antagonist at benzodiazepine binding site on GABA-A receptor
• No intrinsic activity: Does not activate or inhibit on its own
• Reverses all effects: Anxiolysis, sedation, amnesia, muscle relaxation

Pharmacokinetics:

• Onset: 1-2 minutes
• Peak effect: 5-10 minutes
• Duration: 30-60 minutes (shorter than most benzodiazepines)
• Half-life: 0.7-1.3 hours
• Risk: Resedation when flumazenil wears off

Dosing:

• Initial: 0.2 mg IV over 15 seconds
• Repeat: 0.2 mg q60 seconds to max 1 mg total
• Infusion: 0.1-0.4 mg/hour if prolonged reversal needed (resedation prevention)

Indications:

• Emergency reversal: Respiratory depression, oversedation
• Diagnostic: Rule out benzodiazepine effect in altered mental status
• Paradoxical reaction: Reverse excitation
• Flumazenil challenge: In comatose patient to differentiate benzodiazepine overdose from other causes

Contraindications/Cautions:

• Seizure history: Can precipitate seizures (benzodiazepine withdrawal)
• Tricyclic antidepressant overdose: Can cause seizures, arrhythmias
• Long-term benzodiazepine use: Withdrawal, seizures
• ICU sedation reversal: Monitor for resedation (flumazenil shorter than midazolam)

Side Effects:

• Resedation (most important)
• Seizures (withdrawal)
• Agitation, anxiety
• Flushing
• Dizziness

Comparison with Other Benzodiazepines

Special Populations

Elderly:

• Increased sensitivity: ↓receptor density, ↓clearance
• Prolonged effect: Double half-life
• Dose: Reduce 50% or more
• Risk: Delirium, falls, cognitive impairment
• Avoid: If possible for ICU sedation (delirium risk)

Pediatrics:

• Rapid redistribution: Shorter duration than adults
• Paradoxical excitation: More common (10-15%)
• Respiratory depression: More sensitive (airway obstruction)
• Dosing: Higher mg/kg (liver metabolism faster, larger Vd)
• Use: Effective premedication (PO, buccal, intranasal)

Obesity:

• Dosing: Lean body weight (highly lipophilic, distributes to fat)
• Caution: Sleep apnea (airway obstruction risk)

Pregnancy:

• Category D: Not recommended (cleft palate in animal studies, human data conflicting)
• Labour: Crosses placenta (floppy infant syndrome if near delivery)
• Lactation: Excreted in breast milk (sedation in infant)
• Use only if: Benefits outweigh risks

Hepatic Impairment:

• Effect: Prolonged, potentiated
• Dose: Reduce 50%, avoid or use minimal doses
• Alternative: Lorazepam (glucuronidation less affected)

Renal Impairment:

• Effect: Prolonged (active metabolite accumulation)
• Dose: Reduce 25-50%
• Alternative: Lorazepam (no active metabolites)

ANZCA Primary Exam Focus

Key Concepts

Structure:

• Imidazobenzodiazepine (unique fused imidazole ring)
• Water-soluble at pH <4, lipid-soluble at pH 7.4
• No pain on injection (vs. diazepam)

Mechanism:

• GABA-A receptor allosteric modulator
• Increases chloride conductance (frequency, not duration)
• Binds between α and γ subunits

Pharmacokinetics:

• High lipophilicity (log P 3.2) - rapid CNS entry
• Redistribution terminates effect (short duration)
• CYP3A4 metabolism → active metabolite α-hydroxymidazolam
• Renal excretion of metabolites
• Half-life 1.5-3 hours (longer in elderly, organ dysfunction)

Clinical:

• Anxiolysis, amnesia (anterograde), sedation, anticonvulsant
• Paradoxical reactions (agitation, disinhibition)
• Respiratory depression (synergistic with opioids)
• Flumazenil reversal (competitive antagonist)

Dosing:

• Premedication: 0.02-0.05 mg/kg IV
• Sedation: 0.05-0.1 mg/kg IV
• ICU infusion: 0.03-0.2 mg/kg/hour

Common Exam Questions

"Why does midazolam not cause pain on injection?"

• Water-soluble at acidic pH (commercial preparation pH 3-3.5)
• No organic solvent needed (vs. diazepam which requires propylene glycol)
• After injection, pH 7.4 causes ring opening → becomes lipid-soluble

"Compare midazolam and diazepam."

• Midazolam: Water-soluble, no pain, rapid onset (1-2 min), short duration (2-6 hours), active metabolites, CYP3A4
• Diazepam: Lipid-soluble, painful injection, slower onset (2-5 min), longer duration (4-8 hours), active metabolites (long-acting), multiple CYPs

"What is the mechanism of action of benzodiazepines?"

• GABA-A receptor positive allosteric modulators
• Bind to specific benzodiazepine site (between α and γ subunits)
• Enhance GABA binding and increase chloride conductance
• Hyperpolarize neuron (inhibitory effect)

"How is midazolam metabolized?"

• Hepatic CYP3A4 oxidation
• Active metabolite: α-hydroxymidazolam (50% potency)
• Excreted renally as glucuronide conjugates
• Accumulates in renal failure (active metabolite)

"What are the side effects of midazolam?"

• Respiratory depression (dose-dependent, synergistic with opioids)
• Hypotension (vasodilation)
• Paradoxical excitation (agitation, disinhibition)
• Amnesia (anterograde)
• Prolonged sedation (especially elderly, organ dysfunction)

References

1. ANZCA. Primary Examination Syllabus. Pharmacology Section.
2. Reves JG et al. Midazolam: Pharmacology and uses. Anesthesiology. 1985;62(3):310-324.
3. Greenblatt DJ et al. Benzodiazepines. N Engl J Med. 1983;309(7):410-416.
4. Nordt SP et al. Midazolam: New applications. J Emerg Med. 1997;15(3):409-415.
5. Rung JR et al. Pharmacokinetics of midazolam. Anesthesiology. 1985;63(3):293-296.
6. Blumer JL. Clinical pharmacology of midazolam in infants and children. Clin Ther. 1998;20(5):1049-1060.
7. Reves JG et al. Midazolam for ICU sedation. Crit Care Med. 1984;12(11):939-941.
8. Bailey PL et al. Failure of flumazenil to reverse sedation. Anesthesiology. 1992;76(2):255-260.